The recent population-based study by Ojeda-Fernández et al [1], provides a valuable and timely perspective on the evolving epidemiology of cardiac amyloidosis (CA). Leveraging two decades of administrative data from the Lombardy region, the authors demonstrate a continuous and accelerating rise in CA-related hospitalizations, with a striking post-2016 inflection among elderly males. This epidemiological trajectory is consistent with the growing adoption of non-invasive diagnostic criteria, which has progressively reduced the historical dependence on endomyocardial biopsy.
